Quantification of the Pressure Threshold Related to Tissue Injury in Bedriden Paraplegics
Primary Purpose
Pressure Ulcer, Bedsore, Spinal Cord Injury
Status
Terminated
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Muscle biopsy
Sponsored by
About this trial
This is an interventional prevention trial for Pressure Ulcer focused on measuring Pressure ulcer, Interface pressure, Pressure mapping device, Ischemia reperfusion, Monitoring, Microvascularization
Eligibility Criteria
Inclusion Criteria:
- Educated consent signed,
- Older than 18,
- Paraplegia for at least 6 months,
- Patient's Body Mass Index > 18,5kg/m²,
- Surgery planned for pressure ulcer resection,
- Pressure Ulcer classification (EPUAP) at least III or IV
Exclusion Criteria:
- Cardiac pathology,
- Duchenne muscular dystrophy,
- Dementia,
- Presence of a tumourous wound,
- Stade IV arteritis non-revascularisable,
- Diabetes mellitus,
- Cachexia,
- Impossibility to stop the anti-coagulant treatment 24 hours before the patient admission,
- Xylocaine allergy,
- Patient took aspirin or anti-inflammatory 3 days before the biopsy,
- Patient taking part in another study,
- Patient with no health insurance,
- Pregnant women or breast-feeding, patient unable to give his or her educated consent, ward of the state (art. L.1121-6, L.1121-7, L.1211-8, L.1211-9)
Sites / Locations
- CHU Montpellier
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Arm Label
Time of the first biopsy: H0
Time of the first biopsy: H1
Time of the first biopsy: H2
Time of the first biopsy: H3
Arm Description
For the patients in arm H0, the first biopsy is done as soon as the patient is lying on the air mattress.
For a patient in arm H1, it is done after 1 hour lying on the air mattress.
For a patient in arm H2, it is done after 2 hour lying on the air mattress.
For a patient in arm H3, it is done after 3 hour lying on the air mattress.
Outcomes
Primary Outcome Measures
The interface pressure will be continuously assessed using a mapping device (XSensor) during 3 hours.
Secondary Outcome Measures
The microvascularization changes underneath the compressed skin and the inflammatory response of the muscle cells.
The blood flow, the oxygen saturation and the hemoglobin amount will be measured using a medical device called Oxygen To See (O2C). The reactive oxygen species or ROS and other specific biomarkers will be used to measure and quantify the inflammatory response of muscle cells.
Full Information
NCT ID
NCT02412046
First Posted
April 3, 2015
Last Updated
December 22, 2021
Sponsor
University Hospital, Montpellier
Collaborators
Hill-Rom
1. Study Identification
Unique Protocol Identification Number
NCT02412046
Brief Title
Quantification of the Pressure Threshold Related to Tissue Injury in Bedriden Paraplegics
Official Title
Quantification of the Pressure Threshold Related to Tissue Injury in Bedriden Paraplegics
Study Type
Interventional
2. Study Status
Record Verification Date
December 2021
Overall Recruitment Status
Terminated
Why Stopped
Departure of the PhD in charge of the study
Study Start Date
October 1, 2015 (Actual)
Primary Completion Date
October 2, 2019 (Actual)
Study Completion Date
October 2, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Montpellier
Collaborators
Hill-Rom
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of this study is to correlate the intensity and the duration of a mechanical strain, applied over the skin of a bedridden paraplegics, with the microvascularization parameters (oxygen saturation, blood flow and blood volume) and the early inflammatory mechanism. We want to detect the early stage of irreversible damage for each patient. To achieve this goal, we measure some specifics data over a group of 48 paraplegics admitted in the hospital for a pressure ulcer surgical treatment. The patients are randomly distributed in 4 groups. First the interface pressure between the patient body and the air mattress is recorded continuously for 3 hours (= the repositioning patient frequency): we have the pressure over each point of the patient body in contact with the mattress on this time lap. Then, we will measure the microvascularization parameters, using an O2C medical device over a trochanter on a specific anatomical area which will be thereafter biopsied. Finally, depending on the group in which they were randomly distributed, the patient will undergo a muscle biopsy on his or her trochanter at 0h, 1h, 2h or 3h after they lie down on the air mattress. This way, we will be able to determine the effect of the mechanical strain duration on the physiologic parameters. The following day, the patient is undergoing his or her surgery for removing the necrotic area of the bedsore. At the same time, we will recover some of the sample near the bedsore which would serve as a maximum inflammatory response. Then a second muscle biopsy will be performed on an innervated area to be able to determine a basal concentration of biomarkers.
The inclusion period for this study will be 3 years. All the patients are followed for 24 hours then they will be followed by medical staff in their bedsore resection setting.
The data gained for this study will hopefully help the scientific world to achieve a better understanding of the pressure ulcer aetiology. They will also be helpful to achieve a mobilization of the patient specific of his or her inherent characteristics with a high sensitivity level. This way we will have a more efficient bedsore prevention.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pressure Ulcer, Bedsore, Spinal Cord Injury, Paraplegia
Keywords
Pressure ulcer, Interface pressure, Pressure mapping device, Ischemia reperfusion, Monitoring, Microvascularization
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
21 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Time of the first biopsy: H0
Arm Type
Active Comparator
Arm Description
For the patients in arm H0, the first biopsy is done as soon as the patient is lying on the air mattress.
Arm Title
Time of the first biopsy: H1
Arm Type
Active Comparator
Arm Description
For a patient in arm H1, it is done after 1 hour lying on the air mattress.
Arm Title
Time of the first biopsy: H2
Arm Type
Active Comparator
Arm Description
For a patient in arm H2, it is done after 2 hour lying on the air mattress.
Arm Title
Time of the first biopsy: H3
Arm Type
Active Comparator
Arm Description
For a patient in arm H3, it is done after 3 hour lying on the air mattress.
Intervention Type
Procedure
Intervention Name(s)
Muscle biopsy
Primary Outcome Measure Information:
Title
The interface pressure will be continuously assessed using a mapping device (XSensor) during 3 hours.
Time Frame
The first day of the patient admission (during the first 3 hours).
Secondary Outcome Measure Information:
Title
The microvascularization changes underneath the compressed skin and the inflammatory response of the muscle cells.
Description
The blood flow, the oxygen saturation and the hemoglobin amount will be measured using a medical device called Oxygen To See (O2C). The reactive oxygen species or ROS and other specific biomarkers will be used to measure and quantify the inflammatory response of muscle cells.
Time Frame
The first day of the patient admission (during the first 3 hours).
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Educated consent signed,
Older than 18,
Paraplegia for at least 6 months,
Patient's Body Mass Index > 18,5kg/m²,
Surgery planned for pressure ulcer resection,
Pressure Ulcer classification (EPUAP) at least III or IV
Exclusion Criteria:
Cardiac pathology,
Duchenne muscular dystrophy,
Dementia,
Presence of a tumourous wound,
Stade IV arteritis non-revascularisable,
Diabetes mellitus,
Cachexia,
Impossibility to stop the anti-coagulant treatment 24 hours before the patient admission,
Xylocaine allergy,
Patient took aspirin or anti-inflammatory 3 days before the biopsy,
Patient taking part in another study,
Patient with no health insurance,
Pregnant women or breast-feeding, patient unable to give his or her educated consent, ward of the state (art. L.1121-6, L.1121-7, L.1211-8, L.1211-9)
Facility Information:
Facility Name
CHU Montpellier
City
Montpellier
ZIP/Postal Code
34295
Country
France
12. IPD Sharing Statement
Learn more about this trial
Quantification of the Pressure Threshold Related to Tissue Injury in Bedriden Paraplegics
We'll reach out to this number within 24 hrs